A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

This study is testing a new drug called OPB-101 in women with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that has come back within 6 months of platinum chemotherapy (known as platinum-resistant disease). **You may be eligible if:** - You are 18 or older - You have been diagnosed with high-grade serous ovarian, peritoneal, or fallopian tube cancer - Your cancer came back within 6 months of your last platinum-based chemotherapy - You have received at least 2 prior lines of chemotherapy - You received a PARP inhibitor if you have a BRCA1/2 gene mutation - You are in good physical health with adequate organ function **You may NOT be eligible if:** - You are pregnant or breastfeeding - You have active, uncontrolled infection or autoimmune disease - You have received prior CAR-T cell therapy or mesothelin-targeted therapy - You have active brain metastases or significant lung, heart, or liver disease - You have received chemotherapy within the past 3 weeks Talk to your doctor to see if this trial is right for you.